Quick Answer
A new US Veterans Affairs trial and a 600,000-patient study show GLP-1 drugs like Ozempic may reduce alcohol addiction and cravings. India has over 75 million alcohol-dependent adults who could benefit from this breakthrough.
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
Could the same drug that helps millions lose weight also treat alcohol addiction? New evidence from the United States suggests the answer may be yes — and for India, where over 75 million adults struggle with alcohol use disorder, this development could be transformative. The US Department of Veterans Affairs launched a landmark clinical trial on July 30, 2026, testing semaglutide — the active ingredient in Ozempic and Wegovy — as a treatment for alcohol use disorder. The trial follows a massive study of 600,000 veterans showing GLP-1 drugs reduce substance abuse rates across every major drug class, including alcohol, opioids, cocaine, and cannabis.
What Happened
On July 30, 2026, the Veterans Affairs (VA) health system began recruiting for a randomised clinical trial testing GLP-1 drugs against alcohol use disorder. The trial will enroll 600 veterans at 18 medical centres across the United States. Participants with moderate or severe alcohol use disorder will receive either weekly injections of semaglutide or a placebo for 24 weeks. The VA launched this trial partly based on findings from a study by researchers at Washington University (WashU) School of Medicine, which analysed the health records of over 606,000 US veterans with type 2 diabetes.
The WashU team found that veterans who took GLP-1 drugs were significantly less likely to develop alcohol use disorder, nicotine dependence, cannabis use disorder, cocaine use disorder, and opioid use disorder compared to veterans on other diabetes medications. For those already struggling with addiction, GLP-1 users experienced fewer overdoses, fewer emergency hospitalisations, and fewer drug-related deaths. These were not small effects — across the spectrum of substances studied, GLP-1 users showed meaningful and consistent reductions in addiction risk and harm.
How GLP-1 Drugs Affect the Brain and Cravings
GLP-1 receptors are not found only in the gut and pancreas — they are also present in the brain's reward and motivation circuits, including the dopamine pathways that drive cravings and compulsive behaviour. When GLP-1 drugs activate these brain receptors, they appear to reduce the reward signal that makes alcohol and drugs feel pleasurable. In animal studies, GLP-1 receptor agonists have consistently reduced voluntary alcohol consumption, and early human studies have found that people taking semaglutide report reduced cravings for both food and alcohol.
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
This is a fundamentally different mechanism from current addiction treatments. Most medications for alcohol use disorder — such as naltrexone or acamprosate — work by blocking opioid receptors or reducing withdrawal symptoms. GLP-1 drugs appear to work upstream, quieting the brain's desire for rewarding substances before craving escalates into compulsive use. Researchers at WashU described it as GLP-1 drugs getting at the heart of addiction — not just managing symptoms but potentially addressing the underlying neural drive.
Why This Matters Deeply for India
India carries one of the heaviest burdens of alcohol-related harm in the world. According to the National Mental Health Survey, approximately 22 percent of Indian men are alcohol users, and over 75 million adults meet criteria for alcohol use disorder. India's per-capita alcohol consumption has been rising steadily, and the harms are severe: alcohol use is a major driver of road accidents, domestic violence, liver disease, and premature death. Despite this enormous burden, access to effective addiction treatment in India is extremely limited. Psychiatric services are scarce, behavioural therapy programmes are largely absent outside major cities, and the medications that exist — naltrexone, disulfiram — are rarely prescribed because of stigma, side effects, and lack of specialised care.
GLP-1 drugs offer a different possibility: a single medication with a strong safety record, already used for diabetes and weight management in India, that could simultaneously treat obesity, improve metabolic health, and reduce addictive cravings. The fact that GLP-1 drugs reduce cravings for multiple substances — not just alcohol — is particularly significant for patients in India where polysubstance use, such as tobacco combined with alcohol, is common.
Important Caveats: The Trial Is Still Running
It is essential to be clear: the VA trial has only just begun, and results are expected in 2028. The observational study of 600,000 veterans is powerful, but it cannot prove causation — it is possible that patients who chose GLP-1 drugs were healthier or more motivated to change their behaviour in other ways as well. Semaglutide is not currently approved by any health authority — in India or globally — for treating alcohol use disorder or any form of addiction.
Get Free GLP-1 Therapy Consultation
Speak to a specialist — callback within 30 minutes. Free, confidential.
Confidential · No spam · By submitting you consent to our care team calling you
This means GLP-1 drugs should not be sought out specifically to treat alcohol dependence outside a medical supervision context. However, if you or a family member already has obesity or type 2 diabetes and is also struggling with alcohol dependence or tobacco addiction, this is highly relevant information to discuss with a specialist. The emerging evidence suggests that GLP-1 therapy for metabolic reasons may also carry meaningful benefits for addictive cravings — a dual benefit your doctor should be aware of when making treatment decisions.
What Indian Patients Should Do Next
If you have obesity or type 2 diabetes and are also struggling with alcohol use, smoking, or other addictive behaviours, speak to a GLP-1 specialist about how these medications could fit into your overall treatment plan. At MySurgery, our GLP-1 consultations review your full metabolic and health profile — including the intersection of obesity, diabetes, and lifestyle factors that affect both your physical and mental wellbeing.
Call MySurgery at 8588967050 or WhatsApp us to speak with a GLP-1 specialist. Free consultation, callback in 30 minutes.
Disclaimer: This article is based on information published on the referenced websites below and is intended for general awareness only. It is not a substitute for professional medical advice.
References: 1. The Washington Post — Can a GLP-1 treat alcohol disorder? Veterans Affairs starts a study to find out — https://www.washingtonpost.com/health/2026/07/31/can-glp-1-treat-alcohol-disorder-veterans-affairs-starts-study-find-out/ 2. Science AAAS — GLP-1 drugs linked to lower addiction rates in large study of veterans — https://www.science.org/content/article/obesity-drugs-linked-lower-addiction-rates-large-study-veterans 3. WashU Medicine — GLP-1 medications get at the heart of addiction: study — https://medicine.washu.edu/news/glp-1-medications-get-at-the-heart-of-addiction-study/
MySurgery GLP-1 Team
GLP-1 Research & Patient Education
Have questions about GLP-1 Therapy?
Free consultation. Expert doctors. Callback in 30 minutes.